Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Threshold level or not for low-density lipoprotein cholesterol.

P J Barter, F M Sacks

    The American Journal of Managed Care
    |June 1, 2001
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Protein-based HDL subspecies: Rationale and association with cardiovascular disease, diabetes, stroke, and dementia.

    Biochimica et biophysica acta. Molecular and cell biology of lipids·2022
    Same author

    Effects of dietary carbohydrate on 1,5-anhydroglucitol in a population without diabetes: results from the OmniCarb trial.

    Diabetic medicine : a journal of the British Diabetic Association·2017
    Same author

    Markers of dietary protein intake are associated with successful weight loss in the POUNDS Lost trial.

    Clinical obesity·2017
    Same author

    Thyroid hormones and changes in body weight and metabolic parameters in response to weight loss diets: the POUNDS LOST trial.

    International journal of obesity (2005)·2017
    Same author

    Two-year changes in circulating adiponectin, ectopic fat distribution and body composition in response to weight-loss diets: the POUNDS Lost Trial.

    International journal of obesity (2005)·2016
    Same author

    Plaque stabilizing effects of apolipoprotein A-IV.

    Atherosclerosis·2016

    Researchers debate the optimal low-density lipoprotein cholesterol (LDL-C) threshold for heart disease prevention. Some suggest a 125 mg/dL limit, while others find no evidence of a threshold, raising concerns about costs and safety.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Public Health

    Background:

    • Statins and other therapies effectively lower low-density lipoprotein cholesterol (LDL-C).
    • A key clinical question is whether a minimum LDL-C threshold exists below which coronary heart disease (CHD) risk no longer decreases.

    Purpose of the Study:

    • To evaluate the existence of a lower threshold for LDL-C reduction in relation to coronary heart disease events.
    • To analyze the implications of setting a clinical guideline for LDL-C levels.

    Main Methods:

    • Review and analysis of data from multiple clinical trials and primary prevention studies.
    • Comparative evaluation of different interpretations of existing research data.

    Main Results:

    Related Experiment Videos

  • Some analyses suggest no significant decrease in coronary event rates at or below 125 mg/dL LDL-C, proposing this as a clinical guideline.
  • Other analyses of the same data conclude that no such threshold exists.

    • Conclusions:

    • The decision on whether to implement an LDL-C threshold impacts healthcare costs, potential unknown clinical events, and resource allocation.
    • Further research is needed to clarify the safety and efficacy of very low LDL-C levels and inform clinical practice guidelines.